Technology
Health
Biotechnology

Tocagen

$10.11
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.28 (-2.69%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Tocagen and other stocks, options, ETFs, and crypto commission-free!

About

Tocagen Inc. Common Stock, also called Tocagen, is a clinical-stage, cancer-selective gene therapy compan. Read More It focuses on the development of product candidates designed to activate a patient's immune system against their own cancer from within. It is in the business of discovery, development, and commercialization of products for the treatment of cancer. The company was founded by Thomas E. Darcy, Harry E. Gruber, Douglas J. Jolly, and Dennis N. Berman in August 2007 and is headquartered San Diego, CA.

Employees
79
Headquarters
San Diego, California
Founded
2007
Market Cap
238.97M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
193.53K
High Today
$10.39
Low Today
$9.92
Open Price
$10.24
Volume
63.18K
52 Week High
$15.80
52 Week Low
$6.47

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Therapy
2017 IPO
US

News

Yahoo FinanceMar 11

Implied Volatility Surging for Tocagen (TOCA) Stock Options

Investors in Tocagen Inc. TOCA need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 21, 2019 $15 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also ...

131
MarketBeatMar 7

Stock Price, News, & Analysis for Tocagen

Tocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is als...

9
Seeking AlphaFeb 28

Tocagen: A Valuation

Tocagen Inc. (TOCA) is a clinical-stage company engaged in developing selective gene therapy for various cancers. The company's platform uses retroviral replicating vectors technology and its lead drug candidate is a combo of Toca 511 and Toca FC in Phase III clinical trial targeting recurrent high-grade glioma. We recently covered Tocagen in a report. This valuation article is a follow up. The Valuation sheet is available here. The valuation sheet for the company stock is divided into three sheets where A...

136

Earnings

-$0.96
-$0.65
-$0.33
-$0.02
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 9, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.